2) Ko H, Han JH, Kim EJ, Lim J, Sim M, Lee WH. [The relationship between cognitive function and psychosocial function in chronic schizophrenia patients]. Kor J Clin Psychol 2017 36:10-19. Korean.
3) Jeon DW, Jung DU, Kong BG, Kang JW, Moon JJ, Shim JC. [A review of pharmacological strategy for cognitive deficits in schizophrenia]. Korean J Schizophr Res 2014 17:55-62. Korean.
5) Green MF. Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol 2007;3:159-180.
6) Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301-307.
8) Jo YT, Joo YH. [Changes in the DSM diagnostic concept of schizophrenia: from 1980 to 2013]. J Korean Neuropsychiatr Assoc 2021 60:241-252. Korean.
9) Barch DM, Bustillo J, Gaebel W, Gur R, Heckers S, Malaspina D, et al. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr Res 2013;150:15-20.
14) Seo L, Sung GH, Kim JH, Hwang ST, Park K, Chey J, et al. [K-WAIS-IV profile in schizophrenia]. Kor J Clin Psychol 2014 33:719-734. Korean.
15) Fuentes-Durá I, Ruiz JC, Dasí C, Navarro M, Blasco P, Tomás P. WAIS-IV performance in patients with schizophrenia. J Nerv Ment Dis 2019;207:467-473.
16) Moon HW, Kim CE, Han IS, Lee JS, Bae JN, Kang MH. [Intellectual changes in the patients with schizophrenia]. Korean J Schizophr Res 2003 6:63-69. Korean.
17) Thippaiah SM, Fargason RE, Birur B. Switching antipsychotics: a guide to dose equivalents. Curr Psychiatry 2021;20:13-14.
18) Ayesa-Arriola R, Rodriguez-Sanchez JM, Gomez-Ruiz E, Roiz-Santiáñez R, Reeves LL, Crespo-Facorro B. No sex differences in neuropsychological performance in first episode psychosis patients. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:149-154.
22) Pu C, Qiu Y, Zhou T, Yang F, Lu Z, Wang C, et al. Gender differences of neurocognitive functioning in patients with first-episode schizophrenia in China. Compr Psychiatry 2019;95:152132.
23) Mu L, Liang J, Wang H, Chen D, Xiu M, Zhang XY. Sex differences in association between clinical correlates and cognitive impairment in patients with chronic schizophrenia. J Psychiatr Res 2020;131:194-202.
24) Ruiz JC, Fuentes I, Dasi C, Navarro M. Gender differences on the WAIS-IV in patients with schizophrenia. Salud Ment 2021;44:17-23.
25) Mendrek A, Mancini-Marïe A. Sex/gender differences in the brain and cognition in schizophrenia. Neurosci Biobehav Rev 2016;67:57-78.
26) Ko MA, Lee SK, Lee JS. [Comparative study of clinical features between early- and late-onset schizophrenia in South Korea]. Korean J Schizophr Res 2019 22:51-55. Korean.
27) Fu S, Czajkowski N, Torgalsbøen AK. Cognitive improvement in first-episode schizophrenia and healthy controls: a 6-year multi-assessment follow-up study. Psychiatry Res 2018;267:319-326.
29) Dickson H, Hedges EP, Ma SY, Cullen AE, MacCabe JH, Kempton MJ, et al. Academic achievement and schizophrenia: a systematic meta-analysis. Psychol Med 2020;50:1949-1965.
30) Russell AJ, Munro JC, Jones PB, Hemsley DR, Murray RM. Schizophrenia and the myth of intellectual decline. Am J Psychiatry 1997;154:635-639.